A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy

Trial Profile

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 04 Jul 2015 Trial design presented at the 17th World Congress on Gastrointestinal Cancer.
    • 31 May 2014 Planned number of patients changed from 52 to 42 according to the trial protocol presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top